Merck & Co Inc (MRK.N)
47.33USD
4:00pm EDT
$0.62 (+1.33%)
$46.71
$46.43
$47.44
$46.42
7,177,918
3,949,129
$48.78
$37.02
MRK.N
About
Overall
| Beta: | 0.58 |
| Market Cap (Mil.): | $141,046.09 |
| Shares Outstanding (Mil.): | 3,019.61 |
| Dividend: | 0.43 |
| Yield (%): | 3.68 |
Financials
| MRK.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 23.81 | 35.19 | 35.42 |
| EPS (TTM): | 1.96 | -- | -- |
| ROI: | 7.18 | 19.50 | 18.86 |
| ROE: | 11.16 | 20.27 | 19.73 |
Merck halts development of experimental Parkinson's drug
May 23 - Merck & Co has ended development of preladenant, an experimental drug for Parkinson's disease, after initial data from three late-stage trials proved disappointing.
UPDATE 2-Merck's insomnia drug moves a step closer to U.S. approval
* FDA panel says suvorexant safe, effective at lower doses
FDA panel says Merck's sleep drug safe, effective at lower dose
WASHINGTON - Merck & Co's experimental insomnia drug was safe and effective at the lower of two doses studied, a panel of medical experts said on Wednesday, increasing the chance it will be approved by the U.S. Food and Drug Administration.
UPDATE 1-FDA panel says Merck's sleep drug safe, effective at lower dose
WASHINGTON, May 22 - Merck & Co's experimental insomnia drug was safe and effective at the lower of two doses studied, a panel of medical experts said on Wednesday, increasing the chance it will be approved by the U.S. Food and Drug Administration.
Merck sales representative claims sexual bias, seeks over $100 million
- A sales representative for Merck & Co. filed a more than $100 million sex discrimination lawsuit against the drugmaker on Thursday, claiming that it particularly discriminates against pregnant employees and women with children.
Merck sales rep alleges sexual bias, seeks over $100 mln
May 9 - A senior sales representative for Merck & Co has sued the drugmaker for more than $100 million, alleging the drugmaker discriminates against female employees in terms of pay and advancement, particularly pregnant employees and female employees with children.
FDA approves Merck combination cholesterol lowering pill
- The U.S. Food and Drug Administration approved a Merck & Co cholesterol lowering pill that combines a generic version of Pfizer Inc's Lipitor with its own Zetia, Merck said on Friday.
Fitch Affirms Merck & Co.'s IDR at 'A+'; Outlook Negative
(The following statement was released by the rating agency) CHICAGO, May 03 (Fitch) Fitch Ratings has affirmed Merck & Co.'s (Merck) ratings, including the Issuer Default Rating (IDR) at 'A+'. The Rating Outlook is revised to Negative from Positive. A full list of ratings affirmed is listed below. The ratings apply to approximately $20.5 billion in outstanding debt. KEY RATING DRIVERS Leveraging Share-Buybacks Pressure Credit Profile On April 1, Merck announced the expansion of its share re
Wall Street drops on data, earnings; Facebook up late
NEW YORK - Stocks fell sharply on Wednesday as the latest economic data continued a trend of indicators pointing to anemic growth while bellwether companies disappointed on revenue. | Video
Merck's Januvia diabetes drug lags, 2013 forecast cut
- Merck & Co Inc reported a surprising drop in quarterly sales of diabetes medicine Januvia, its biggest product and a frequent driver of quarterly earnings, and the drugmaker cut its full-year profit forecast on Wednesday.
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $87.21 | -0.59 |
| Pfizer Inc. (PFE.N) | $29.11 | -0.19 |
| Abbott Laboratories (ABT.N) | $37.48 | -0.24 |
| Eli Lilly & Co. (LLY.N) | $54.74 | -0.18 |
| Bristol Myers Squibb Co. (BMY.N) | $47.00 | +0.60 |
| Bristol Myers Squibb Co. (BMY_p.N) | $567.60 | 0.00 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Trading Report for (MRK). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Market Edge
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
